Genome Editing Market (By Technology: CRISPR/Cas9, ZFN; By Delivery Method: Ex-vivo, In-vivo; By Application; By Mode; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Genome Editing Market Size and Growth

The global genome editing market size was estimated at USD 7.98 billion in 2023 and is expected to surpass around USD 38.26 billion by 2033, poised to grow at a CAGR of 16.97% from 2024 to 2033.

Key Pointers

• North America led the market with the largest market share of 48% in 2023.
• Asia Pacific is anticipated to witness the fastest growth at a CAGR of 18.76% from 2024 to 2033.
• By Technology, the CRISPR/Cas9 segment generated the maximum market share of 44% in 2023.
• By Technology, the ZFN segment is expected to expand at the highest CAGR of 16.57% from 2024 to 2033.
• By Delivery Method, the ex-vivo segment dominated the market with a share of 52% in 2023.
• By Delivery Method, the in-vivo segment is estimated to expand the fastest CAGR of 19.95% from 2024 to 2033.
• By Application, the genetic engineering segment held the largest market share in 2023.
• By End-use, the biotechnology and pharmaceutical companies segment accounted for the largest market share of 51% in 2023.

Genome Editing Market Overview

Genome editing, also known as gene editing, refers to a set of technologies that enable scientists to alter an organism's DNA. These technologies allow for the addition, removal, or modification of genetic material at particular locations in the genome. The advancements in this field have opened up numerous possibilities across various sectors, including healthcare, agriculture, and biotechnology.

Genome Editing Market Growth Factors

The growth of the genome editing market is fueled by an advancements in technology, particularly the development of highly efficient and precise genome editing tools like CRISPR-Cas9, have accelerated research and applications across various sectors. Additionally, increasing investment in research and development activities by both public and private entities has contributed to expanding the scope and capabilities of genome editing techniques. Moreover, the rising prevalence of genetic disorders and the need for effective treatments have spurred demand for genome editing in the healthcare sector.

U.S. Genome Editing Market Size 2024 to 2033

The U.S. genome editing market size was estimated at around USD 2.68 billion in 2023 and it is projected to hit around USD 12.85 billion by 2033, growing at a CAGR of 16.97% from 2024 to 2033.

The presence of robust research infrastructure, a rise in genetically modified crops, and an increase in the prevalence of genetic diseases are some of the major factors boosting the U.S. genome editing market’s growth. Moreover, in the U.S., genetic diseases such as cystic fibrosis are prevalent. On the other hand, a rise in the number of patent approvals for U.S.-based companies has also accelerated the adoption of genome editing tools in the country, leading to positive market growth.

North America dominated the market and accounted for a 48% share in 2023 owing to the growing investments in the R&D of gene editing technologies. Due to the presence of several biotechnology and pharmaceutical companies working on developing genome editing technologies, the region is projected to maintain its dominance over the projected period.

Asia Pacific is anticipated to witness the fastest growth at a CAGR of 18.76% from 2024 to 2033. The regional market growth is expected to be driven by the increasing demand for gene editing technologies and the rising prevalence of genetic disorders and diseases across countries like India and Australia. Moreover, the domestic companies providing gene editing products and services are attracting investments and funding. For instance, in April 2021, GenScript launched Research-Grade Lentiviral Vector Packaging Service for drug discovery, cell line development, and gene editing.

Genome Editing Market Trends:

• Growing Applications in Healthcare: Genome editing technologies are increasingly utilized in healthcare for therapeutic purposes, including the treatment of genetic disorders, cancer, and infectious diseases. The potential for personalized medicine and targeted therapies is driving significant research and development efforts.
• Expansion in Agricultural Biotechnology: The agriculture sector is embracing genome editing to develop crops with desirable traits such as improved yield, resistance to pests and diseases, and enhanced nutritional content. This trend is driven by the need to address global food security challenges and optimize agricultural productivity.
• Rising Investment in Research and Development: Public and private investments in genome editing research and development are increasing globally. Funding is directed towards advancing technology, exploring new applications, and addressing safety and ethical concerns associated with gene editing.
• Emergence of CRISPR-based Therapeutics: CRISPR-based therapeutics, including gene therapies and genome editing drugs, are gaining traction in clinical trials and regulatory approvals. These therapies hold promise for treating a wide range of diseases and disorders, driving growth in the biopharmaceutical sector.
• Regulatory Landscape and Ethical Considerations: Regulatory frameworks surrounding genome editing are evolving to address safety, ethical, and societal concerns. Guidelines and guidelines are being developed to ensure responsible and ethical use of gene editing technologies across different sectors.
• Focus on Off-target Effects and Safety: Efforts to improve the specificity and safety of genome editing tools are intensifying, with researchers focusing on minimizing off-target effects and enhancing control over gene editing processes.

Genome Editing Market Restraints:

• Off-target Effects and Safety Concerns: Despite advancements, genome editing technologies such as CRISPR-Cas9 may still exhibit off-target effects, leading to unintended genetic modifications. Concerns about the safety and potential long-term consequences of gene editing in humans and other organisms pose significant challenges to widespread adoption.
• Ethical and Regulatory Hurdles: Ethical considerations surrounding genome editing, including questions of consent, equity, and the potential for misuse, present regulatory challenges. There is ongoing debate and uncertainty regarding the appropriate ethical guidelines and regulatory frameworks governing gene editing technologies.
• Intellectual Property Rights and Patent Disputes: The genome editing field is characterized by intense competition and disputes over intellectual property rights and patents. Legal battles and uncertainties surrounding patent ownership and licensing agreements can hinder innovation and investment in the market.
• Public Perception and Acceptance: Public perception of genome editing technologies, particularly in the context of human germline editing, varies widely and can influence regulatory decisions and funding priorities. Lack of public acceptance or perceived risks associated with gene editing may impede market growth and adoption.
• Complexity and Cost of Implementation: Implementing genome editing technologies in research and commercial settings can be complex and expensive. High costs associated with equipment, reagents, and specialized expertise may limit accessibility and adoption, particularly in resource-constrained settings.
• Biosecurity and Dual-Use Concerns: Genome editing technologies have the potential for both beneficial and harmful applications, raising concerns about biosecurity and dual-use risks. Safeguarding against misuse or unintended consequences of gene editing requires robust oversight and international collaboration.

Technology Insights

The CRISPR/Cas9 segment held the largest market share of 44% of the global revenue in 2023. This can be attributed to high precision & efficiency, high versatility & adaptability to different experimental designs, and cost-effectiveness with relatively low expense associated. In addition, with the growing number of applications, the demand for CRISPR is anticipated to grow over the forecast period. The clinical applications of CRISPR have been widely accepted. This is evident from the increasing number of ongoing clinical trials using gene-editing techniques for the treatment of a wide range of diseases such as AIDS, cancer, and genetic diseases. In addition to human health, this technology is witnessing increasing usage in agriculture and animal breeding applications.

The ZFN segment is expected to witness a substantial CAGR of 16.57% over the forecast period. Zinc Finger Nuclease (ZFN) is a widely used technology in the field of genome editing. It is a kind of engineered nuclease that facilitates targeted modifications in DNA strands. ZFNs or homing endonucleases have been successfully used to target HBV, HIV, human papillomavirus, herpes simplex virus type, and human T-cell leukemia virus types, as these are susceptible to transcriptional suppression and gene disruption by ZFNs. Moreover, lower off-target activity does aid in gaining the approval for ZFNs as therapies. As a result, the technique is anticipated to hold immense economic potential for developing gene therapies in the coming years.

Delivery Method Insights

The ex-vivo segment dominated the market with a share of 52% in 2023. This dominance can be attributed to the ease of control in DNA modification provided along with the precise regulation of strength and duration of nuclease expression to minimize off-target editing and maximize efficiency. Ex-vivo products such as CAR-T technology for oncology blood treatment are observed to be prioritized in the therapeutic molecular scissors pipeline.

The in-vivo segment is projected to witness the fastest growth at a CAGR of 19.95% from 2024 to 2033. Many specialized cell types cannot be removed from the patient and maintained alive outside the body for the duration of the treatment or cannot be effectively returned to the patient after treatment (e.g., heart muscle cells, specialized neuronal cells). Therefore, the development of several in-vivo genome editing techniques is expected to drive market growth in the near future.

Application Insights

The genetic engineering segment held the largest market share in 2023. The segment is further categorized into cell line engineering, animal genetic engineering, plant genetic engineering, and others. The use of gene therapy for developing novel molecules for the treatment of diseases such as lymphoma, sickle cell, and infectious diseases is anticipated to boost the adoption toward the end of the forecast period.

The clinical applications segment is expected to grow at a significant CAGR of 13.20% over the forecast period. Clinical applications of genome editing include diagnostics and therapy development. The demand for such applications is primarily driven by their potential to address genetic diseases. Genome editing offers the prospect of precise and personalized treatments tailored to an individual's genetic makeup, which helps in advancing therapeutic development. Furthermore, advancements in genome editing technologies, coupled with an increase in understanding of the genetic basis of diseases, have fueled interest in the development of novel diagnostic tools, thereby driving the segment.

Mode Insights

The contract segment dominated the market in 2023 due to the high extent of outsourcing activities in the genomics space driven by the lower costs and greater flexibility in operations offered by such activities as compared to in-house development. The segment is projected to witness further growth because of the increasing strategic activities undertaken by outsourcing service providers. For instance, in December 2022, a CRO named Crown Bioscience, Inc. collaborated with ERS Genomics Limited to gain access to ERS’ CRISPR/Cas9 patent portfolio and strengthen its market presence in the gene editing space. Such initiatives are expected to boost the outsourcing opportunities in the genome editing domain and can positively impact market growth.

The in-house segment is expected to witness lucrative growth over the forecast period due to the ownership of supply channels, better troubleshooting abilities, and enhanced potential for future in-house scale-up activities. Hence, companies such as Precision BioSciences maintain internal manufacturing facilities compliant with current Good Manufacturing Practices (cGMP) to produce genome-edited products, including allogeneic CAR T cell therapies. These factors are anticipated to drive the revenue growth for the segment over the forecast period.

End-use Insights

The biotechnology and pharmaceutical companies segment accounted for the largest market share of 51% in 2023. The presence of a growing number of research activities for novel therapeutic development is the major factor contributing to revenue generation. Moreover, global pharmaceutical companies are collaborating with emerging companies to develop novel technologies. Increased research development efforts for novel treatments are the main factor fueling revenue growth. With rapid advancements in DNA engineering technology such as the introduction of the CRISPR/Cas9 system, the process of creating knockout/knock-in transgenic in microorganisms, plants, and animals, including humans, has become very simple, easy, efficient, accurate, and less time-consuming.

The academic and research institutions segment is expected to grow at the fastest CAGR of 19.23% over the forecast period due to the increasing usage of genome editing technology in academic settings such as college campuses. Several organizations are developing lessons for high school and college students to better understand gene editing techniques.

Genome Editing Market Key Companies

• Merck KGaA
• Cibus Inc.
• Recombinetics
• Sangamo Therapeutics
• Editas Medicine
• Precision BioSciences
• CRISPR Therapeutics
• Intellia Therapeutics, Inc.
• Caribou Biosciences, Inc
• Cellectis S.A.
• AstraZeneca
• Takara Bio Inc.
• Horizon Discovery Ltd. (Revvity, Inc.)
• Danaher Corporation
• Transposagen Biopharmaceuticals, Inc.
• Genscript Biotech Corp
• New England Biolabs
• OriGene Technologies, Inc.
• bluebird bio, Inc.
• Lonza
• Thermo Fisher Scientific, Inc

Recent Developments

• In November 2023, Cellectis and AstraZeneca entered into a collaboration agreement to accelerate advanced therapeutics development in oncology and immunology.
• In July 2023, Sangamo Therapeutics and Chroma Medicine collaborated to develop epigenetic medicines using Sangamo's Zinc Finger Proteins (ZFPs). Chroma will evaluate ZFPs for specific targets outside the central nervous system, potentially licensing them for development and commercialization.
• In May 2023, a research program at the Lewis Katz School of Medicine at the University of Nebraska Medical Center reported successful treatment of HIV infection in animals using CRISPR.
• In April 2022, LGC acquired Rapid Genomics to enhance its position in NGS application for high-throughput genotyping in the agrigenomics market.

Genome Editing Market Segmentation:

By Technology

• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• Others

By Delivery Method

• Ex-vivo
• In-vivo

By Application

• Genetic Engineering
  • Cell line engineering
  • Animal genetic engineering
  • Plant genetic engineering
  • Others
• Clinical Applications
  • Diagnostics
  • Therapy Development

By Mode

• Contract
• In-house

By End-use

• Biotechnology and pharmaceutical companies
• Academic and government research institutes
• Contract research organizations

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• MEA